🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against drug-resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting in excess of 82 million instances each year. Particularly high rates are reported in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Health officials are deeply concerned about the surge in drug-resistant strains. The World Health Organization has listed it as a "high-priority threat". Recent surveillance revealed that resistance to standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

Zoliflodacin, also known as Nuzolvence, was approved by the US FDA in recent days for use against gonorrhoea. This infection can lead to major issues, including infertility. Researchers hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, developed by the drugmaker GSK, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment stemmed from a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This authorization marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been outpacing medical innovation.”

Testing Results and Worldwide Availability

As per findings detailed in a major medical journal, zoliflodacin cured the vast majority of cases of the STI. This establishes an similar efficacy with the current standard treatment, which combines two antibiotics. The research involved over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the authority to license and sell the drug in a wide range of developing nations.

Doctors treating patients have shared hope. Having a one-pill regimen of this kind is described as a "revolutionary step" for managing the epidemic. This is viewed as vital to alleviate the strain of the illness for people and to stop the proliferation of untreatable gonorrhoea around the world.